Abclon Inc. (174900)
Market Closed
10 Aug, 06:30
KRX SM KRX SM Primary ₩
34,700. 00
+6,700
+23.9286%
₩
777.08B Market Cap
- P/E Ratio
- Div Yield
535,264 Volume
- Eps
₩ 28,000
Previous Close Want to track 174900 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
174900 closed today higher at ₩34,700, an increase of 23.9286% from yesterday's close, completing a monthly increase of 24.5961% or ₩6,850. Over the past 12 months, 174900 stock lost -20.2299%.
174900 is not paying dividends to its shareholders.
Abclon Inc. has completed 1 stock splits, with the recent split occurring on Jul 16, 2020.
The company's stock is traded on one exchange.
Abclon Inc. (174900) FAQ
What is the stock price today?
The current price is ₩34,700.00.
On which exchange is it traded?
Abclon Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 174900.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 777.08B.
Has Abclon Inc. ever had a stock split?
Abclon Inc. had 1 splits and the recent split was on Jul 16, 2020.
Abclon Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | KR7174900001 ISIN |
| South Korea Country | - Employees | - Last Dividend | 16 Jul 2020 Last Split | - IPO Date |
Overview
AbClon Inc. operates in the biotechnology industry focusing on the research and development of innovative antibody drugs. Established in 2010, the company has its roots in Seoul, South Korea, and extends its operations to Sweden. AbClon is dedicated to creating a new generation of targeted therapies for a variety of cancers and autoimmune diseases. The company leverages advanced biotechnological platforms to develop its products, aiming to address unmet medical needs in oncology and immunology.
Products and Services
AbClon Inc. has developed a robust pipeline of products based on proprietary platform technologies, targeting several challenging medical conditions:
- NEST Platform Technology Products: This cutting-edge technology is designed to target breast and gastric cancers. Through precision medicine, the NEST platform aims to develop therapeutic antibodies that can more effectively target cancer cells, potentially leading to higher efficacy and lower toxicity than existing treatments.
- AffiMab Platform Technology Products: Focused on colon cancer and autoimmune diseases, the AffiMab platform utilizes novel bioengineering approaches to create antibodies with enhanced binding affinity and specificity. These products are designed to offer new options for treatment-resistant diseases, improving patient outcomes and quality of life.
- CAR-T Platform Technology Products: Catering to hematologic and ovarian cancers, AbClon's CAR-T technology represents a frontier in cancer immunotherapy. By genetically engineering patients' T-cells to recognize and kill cancer cells, this approach offers a powerful and personalized treatment option for individuals with these challenging conditions.
Contact Information
Address: 1401 285, Digital-ro
Phone: 82 2 2109 1294
Website: https://www.abclon.com
